Core Viewpoint - Recently, Huatai Medical announced the results of a share reduction by a shareholder holding more than 5% of the company's shares, indicating a significant transaction involving the company's vice chairman and general manager, Cheng Zhenghui, who reduced his stake at a price substantially lower than the market price [1] Group 1 - Cheng Zhenghui reduced his stake by 2% through block trading from September 3 to September 11, 2025 [1] - The reduction price was significantly lower than the market price, with Huatai Medical's stock price remaining above 300 yuan during the reduction period [1] - On September 11, 2025, Huatai Medical's closing price was 309.53 yuan, approximately 25% higher than the block trading transaction price of 248.20 yuan [1] Group 2 - The buyer of the reduced shares was Shenzhen Mindray Technology Holdings Co., Ltd., which became the controlling shareholder of Huatai Medical last year [1] - Shenzhen Mindray is a wholly-owned subsidiary of Mindray Medical, a leading player in the A-share medical device sector [1]

Group 1 - The core point of the article is the significant share reduction by the vice chairman and general manager of Huitai Medical, Cheng Zhenghui, who sold 2% of his shares at a price significantly lower than the market price, with the buyer being Shenzhen Mindray Technology, the controlling shareholder of Huitai Medical [1][2][5] - Cheng Zhenghui reduced his holdings from 25,373,507 shares to 23,551,232 shares, lowering his ownership percentage to 16.70% [2][5] - The share reduction occurred between September 3 and September 11, 2025, at a price of 248.20 yuan per share, totaling nearly 700 million yuan, while the market price was above 300 yuan during that period [2][5][10] Group 2 - Shenzhen Mindray Technology increased its stake in Huitai Medical by acquiring 2,164,739 shares on September 11, 2025, raising its total holdings from 35,253,449 shares to 37,418,188 shares, resulting in a new ownership percentage of 26.54% [5][9] - Huitai Medical has shown impressive growth, with revenue increasing from 479 million yuan in 2020 to 2.066 billion yuan in 2024, and net profit rising from 111 million yuan to 673 million yuan during the same period [9][10] - In the first half of 2025, Huitai Medical reported revenue of 1.214 billion yuan, a year-on-year increase of 21.26%, and net profit of 425 million yuan, up 24.11% [10]

Group 1 - The company Huatai Medical (688617.SH) announced a notification regarding a change in the equity of a shareholder holding more than 5% of shares, specifically from Mr. Cheng Zhenghui [1] - The notification indicates that the reduction of shares occurred between September 3, 2025, and September 11, 2025 [1]

Core Viewpoint - On September 11, a total of 26 A-share listed companies disclosed their shareholding reduction plans, indicating a trend of insider selling in the market [1][2]. Group 1: Company Buybacks - Baicheng Pharmaceutical's controlling shareholder adjusted the upper limit of its buyback plan to no more than 80 yuan per share [2]. Group 2: Company Reductions - Notable companies with planned reductions include: - Zhenghai Magnetic Materials: Directors Gao Bo and Shi Bingqiang plan to reduce their holdings [2]. - Youkede: The actual controller intends to transfer 5.13% of the company's shares at 19.74 yuan per share [2]. - Xinjun Network: Shanghai Senxiao Investment Center reduced its holdings by 1.6271 million shares [2]. - Haige Communication: Shareholder Yang Haizhou plans to reduce holdings by up to 3.5 million shares [2]. - Mind Electronics: Shareholder New大陆 plans to reduce holdings by no more than 1.2% of the company's shares [2]. - Tuoer Si: Shareholder plans to reduce holdings by no more than 0.5% of the company's shares [2]. - Youfang Technology: Some directors and supervisors plan to reduce holdings by no more than 1.3185% of the company's shares [2]. - Juguang Technology: Shareholder Yan Suibin's reduction plan has been completed [2]. - Zhiyuan New Energy: Controlling shareholder's concerted actor Wang Ran plans to reduce holdings by no more than 3% of the company's shares [2]. - Huatai Medical: Vice Chairman Cheng Zhenghui reduced holdings by 2.8203 million shares between September 3 and September 11 [2]. - Shanhaishan: Shareholders Dajiankang and Director Ren Yingxiang plan to reduce holdings by up to 4.08% of the company's shares [2]. - Wanxun Control: Shareholder Zunwei Trading plans to reduce holdings by no more than 2.5 million shares [2]. - Maijie Technology: Shareholder Zhang Meirong plans to reduce holdings by no more than 1% of the company's shares [2]. - Yinghuate: Shareholder Xie Lichuang plans to reduce holdings by no more than 1% of the company's shares [2]. - Jinpu Garden: Shareholder plans to reduce holdings by no more than 4.58% of the company's shares [2]. - Wenzhou Hongfeng: Controlling shareholder Chen Xiao plans to reduce holdings by no more than 12.5 million shares [2]. - Futec Technology: Shareholder Changjiang Weilai Industrial Fund plans to reduce holdings by no more than 3% of the company's shares [2]. - Huahai Chengke: Shareholder Yang Senmao plans to reduce holdings by no more than 3% of the company's shares [2]. - Yizhiming: Actual controller and concerted actors plan to reduce holdings by no more than 7.27 million shares [2]. - Zhongke Environmental Protection: Shareholder plans to reduce holdings by 1.2% of the company's shares [2]. - Zhongwen Online: Shareholder plans to reduce holdings by no more than 2% of the company's shares [2]. - Bidetech: Director and Deputy General Manager He Ming plans to reduce holdings by no more than 0.0466% of the company's shares [2]. - Jihua Group: Director and Vice Chairman Yang Quanming plans to reduce holdings by no more than 0.3% of the company's shares [2]. - Shengke Communication: National Integrated Circuit Industry Investment Fund has reduced holdings by 4.1 million shares [2]. - Suqian Liansheng: Fangyuan Zhihui plans to reduce holdings by no more than 3% of the company's shares [2]. - Jifeng Co., Ltd.: Shareholder Yu Wanli plans to reduce holdings by no more than 2% of the company's total share capital [2].

Group 1 - The core transaction on September 11 involved 2.1647 million shares of Huitai Medical, with a transaction value of 537.28 million yuan, at a price of 248.20 yuan, representing a discount of 19.81% compared to the closing price of the day [1][2] - The buyer was Huatai Securities Co., Ltd., and the seller was CITIC Securities Co., Ltd. [2] - In the last three months, Huitai Medical has recorded a total of three block trades, amounting to 705 million yuan [1] Group 2 - Huitai Medical's closing price on the day was 309.53 yuan, reflecting an increase of 1.21%, with a turnover rate of 1.00% and a total transaction volume of 433 million yuan [1] - The net inflow of main funds for the day was 14.22 million yuan, and over the past five days, the stock has increased by 1.85% with a total net inflow of 152 million yuan [1] - The latest margin financing balance for Huitai Medical was 93.42 million yuan, with an increase of 9.14 million yuan over the past five days, representing a growth rate of 10.85% [1]

Summary of Key Points Core Viewpoint - On September 11, a total of 105 stocks were traded on the block trading platform, with a cumulative trading volume of 217 million shares and a total transaction value of 3.577 billion yuan, indicating active trading in the market [1]. Group 1: Top Block Trades - The highest transaction value was recorded by China Western Electric, with a single transaction amounting to 593 million yuan [1]. - Huatai Medical followed closely with a transaction value of 537 million yuan from one trade [1]. - Other notable stocks included Guangqi Technology, with a transaction value of 230 million yuan, and Huichuan Technology, with 129 million yuan [1]. Group 2: Stock Performance - China Western Electric saw a price increase of 0.78%, closing at 6.47 yuan, with a transaction price of 5.78 yuan, reflecting a discount of 10.66% [1]. - Huatai Medical's stock rose by 1.21%, closing at 309.53 yuan, with a transaction price of 248.20 yuan, showing a discount of 19.81% [1]. - Other stocks with significant price movements included Guangqi Technology (+3.21%), Huichuan Technology (+1.48%), and Tongcheng New Materials (+3.29%) [1].

| 代码 | 简称 | 成交笔 | 大宗交易数量 | 平均成交价格 | 相对收盘价折溢价 | 大宗交易金额 | | --- | --- | --- | --- | --- | --- | --- | | | | 数 | （万股） | （元） | （%） | （万元） | | 688617 | 惠泰医 疗 | 1 | 216.47 | 248.20 | -19.81 | 53728.82 | | 688692 | 达梦数 据 | 1 | 30.39 | 274.54 | -0.89 | 8343.29 | | 688382 | 益方生 物 | 2 | 207.00 | 30.15 | -14.40 | 6241.05 | | 688578 | 艾力斯 | 5 | 48.87 | 104.63 | -9.00 | 5113.27 | | 688472 | 阿特斯 | 2 | 450.00 | 11.29 | -8.80 | 5080.50 | | 688180 | | 1 | 100.00 | 47.40 | -0.69 | 4740.00 | 证券时报·数据宝统计显示，9月11日共有18只科创板股发生大宗交易， ...

减持计划实施前，成正辉持有公司股份2637.1507万股，占公司总股本的18.70%。其持股股份来源包括 IPO前取得1251.1911万股、股权激励取得4.1628万股以及其他方式取得1381.7968万股。此外，成正辉与 温益明构成一致行动人，温益明持股1.9765万股，占比0.01%，二者合计持股2639.1272万股，占比 18.72% 。 减持计划及实施结果 2025年9月12日，深圳惠泰医疗器械股份有限公司发布公告，披露了持股5%以上股东、副董事长兼总经 理成正辉的减持情况。 减持前持股情况 本次权益变动为5%以上股东履行此前披露的减持计划，且为持股5%以上非第一大股东减持，不会导致 公司控股股东及实际控制人发生变化，也不会对公司治理结构及持续经营产生重大影响。截至公告披露 日，成正辉本次减持计划已实施完毕。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可 ...

Core Viewpoint - The company Huatai Medical (688617.SH) has reported that major shareholder Cheng Zhenghui has reduced his stake by 2% through block trading, completing the reduction plan as of September 11, 2025 [1] Summary by Relevant Sections - **Shareholder Activity** - Cheng Zhenghui has reduced his holdings by a total of 2%, amounting to 2.8203 million shares, from September 3 to September 11, 2025 [1] - The reduction has reached the 1% threshold for equity changes, indicating significant shareholder activity [1] - **Completion of Reduction Plan** - The reduction plan has been fully implemented as of the date of the announcement [1]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-044 公司于 2025 年 9 月 11 日收到成正辉先生出具的《关于持股 5%以上股东权 益变动触及 1%刻度暨减持股份结果的告知函》，2025 年 9 月 3 日至 2025 年 9 月 11 日期间，成正辉先生通过大宗交易方式累计减持公司股份 2,820,275 股，占 公司股份总数的 2%，本次权益变动比例触及 1%刻度，截至本公告披露日，本 次减持计划实施完毕。 | 权益变动方向 | 比例增加□ | 比例减少☑ | | --- | --- | --- | | 权益变动前合计比例 | 18.70% | | | 权益变动后合计比例 | 16.70% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ 否☑ | | 本次权益变动情况 深圳惠泰医疗器械股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度 暨减持股份结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董事、高管持股的基本情况 本次减持计划实施前， ...